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Abstract
In recent years the presence of stem cells (hBSCs: human breastmilk-
derived stem cells) and epithelial progenitors has been demonstrated in 
mother’s milk (MM). Stem cells present in samples of fresh MM exhibit a 
high degree of vitality and this makes possible the performance of cell cultures 
and to evaluate the differentiation capacity of the hBSCs. The most important 
datum that expresses the enormous potential of the use of MM stem cells 
is the presence of a cell population capable of differentiating into the three 
mesoderm, endoderm and ectoderm lines. The small number of studies and 
MM samples analyzed and the different sampling methods applied suggest 
standardization in the collection, analysis and culture of MM in future studies, 
in consideration of the well-known extreme variability of MM composition, 
also from the standpoint of cells.
The analysis of literature data confirms the uniqueness of MM and its 
enormous potential.
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Introduction
Mother’s milk (MM) is an active biological 
liquid the composition of which is still not 
completely known. It shows a variability that is 
not only interindividual, but even intraindividual. 
We know that MM in the same woman changes 
both qualitatively and quantitatively in the 
different stages of lactation, during the day 
and even during a single breastfeed, adapting 
qualitatively also to the mother’s and child’s state 
of health. Functionally, it is possible to distinguish 
a nutritional and a bioactive component in 
MM [1]. The latter is composed of growth and 
immunological factors, as well as a conspicuous 
cell component. 
Knowledge on the cell component of MM is 
still scanty. We know that the cell component 
is 104-13x106/ml of MM: essentially, it was 
thought that leukocytes predominated, but 
this observation derived mostly from studies 
performed on bovines and cholesterol [2]. Recent 
data demonstrate that in mature mother’s milk 
(MMM) leukocytes are present in a percentage 
of ≤ 2%, different from colostrum in which from 
13% to 70% of the cell component is represented 
by leukocytes. Thus, most cells present in MMM 
are those of an epithelial nature: lactocytes and 
myoepithelial cells deriving from the ducts and 
alveoli of the lactating mammary gland.
In recent years the presence of stem cells and 
epithelial progenitors has also been demonstrated [3].
Stem cells have been identified in numerous 
tissues of our organism: thanks to their capacity 
to regenerate and differentiate, they play a key 
role in controlling homeostasis and in tissue 
regeneration processes. Different kinds of stem 
cells have been identified on the basis of their 
degree of differentiation: totipotent stem cells 
are capable of differentiating in the three germ 
layers and extraembryonic tissues; pluripotent 
ones differentiate only in the three germ layers; 
multipotent ones (progenitors) are oriented 
cells that produce specialized cells with specific 
functions; unipotent ones are capable of dif- 
ferentiating into a single cell line.
It is possible to distinguish the different cell 
populations by means of flow cytometry and 
immunofluorescence which allow identification 
of specific surface markers or transcription factors 
(TFs). Stem cells present in samples of fresh MM 
exhibit a high degree of vitality and this makes 
possible the performance of cell cultures and to 
evaluate the differentiation capacity of the human 
breastmilk-derived stem cells (hBSCs).
We shall see that on the basis of data now 
available MM is a quite promising source of stem 
cells with the therapeutic implications deriving 
from them.
Stem cells of mother’s milk (human breastmilk-
derived stem cells): a heterogeneous popula- 
tion 
Research into and studies of stem cells in 
mother’s milk are of recent interest. In 2007, 
Cregan demonstrated the presence of multipotent 
stem cells in MM for the first time [3].
Based on knowledge at hand, we know that 
MM contains a heterogeneous population of stem 
cells with an evolutionary hierarchy: thus it is 
possible to find in it immature pluripotent cell 
forms as well as the more mature committed or 
unipotent forms.
Epithelial stem cells
In MM, the presence of stem cells belonging 
to the mammary line CK5, CK14 and CK18 has 
been demonstrated. Such antigens are in fact the 
expression of the degree of differentiation of 
mammary epithelial cells. CK5 is the marker of 
mammary progenitors, while CK14 and CK18 are 
specific antigens present on the cells of the two 
mature mammary epithelial lines (myoepithelial 
and luminal/ductal cells) [3-5].
In the same way, cells of the neuroepithelial 
kind have also been found with different degrees 
of differentiation, as demonstrated by cell 
positivity to nestin, Msi-1 and NFM, respectively 
markers of progenitors and early and late neural 
differentiation [3, 6]. 
3/5
Journal of Pediatric and Neonatal Individualized Medicine • vol. 5 • n. 1 • 2016 www.jpnim.com Open Access
Mesenchymal stem cells
Also recognized within the cell component of 
MM, although in a small percentage, is the presence 
of specific markers of mesenchymal stem cells 
(MSCs) [5-8]. The MSCs represent about 10% to 
15% of the entire cell population of MM [7].
In a study conducted in 2013 on 26 milk samples, 
besides the progenitors of CD29 and CD44 of the 
myoepithelial cells, MSCs that express the typical 
markers CD90, CD105 and CD73 were isolated [9]. 
Human breastmilk-derived stem cells and 
embryonic stem cells
In 2012, Hassiotou demonstrated the presence 
of hBSCs that express the TFs OCT4, SOX2 and 
NANOG typical of embryonic stem cells (hESC) in 
fresh MM [10]. Compared to the hESC cells, the 
hBSCs of MM express the ESC genes with lower 
values and the three TFs. NANOG is expressed at 
higher levels in tested samples of fresh MM and is, 
among the TFs, the one that plays a leading role in 
controlling the state of cell pluripotency. 
When such cells reproduce, they conserve these 
markers, but they are also capable of differentiating 
into cells of the mammary line, lactocytes and 
myoepithelial cells, capable of producing and 
secreting milk, but also capable of differentiating 
into cells of different lines belonging to the three 
germ layers. They are thus pluripotent cells [10]. In 
MM, the cells that express ESC genes are not all at 
the same stage of development, nor do they have 
the same potential to self-replicate or differentiate. 
In fact, in culture they can differentiate as follows: 
a. ESC-like cells that form colonies similar to 
ESCs;
b. non-ESC-like cells that form colonies with vari- 
able morphology, either mesenchymal-like or 
epithelial-like or mixed, and express reduced 
levels of TFs (TRA-1-60/TRA-1-81). These 
colonies most likely originate from expansion 
of clones of more oriented progenitors in 
which the ESC genes are not completely under-
regulated [10]. 
The most important datum that expresses the 
enormous potential of the use of MM stem cells 
is the presence of a cell population capable of 
differentiating into the three mesoderm, endoderm 
and ectoderm lines. In fact, after 2 to 3 weeks of cul- 
ture in specific growth media, the hBSCs are ca- 
pable of forming colonies having different mor- 
phologies and belonging to different cell lines [6-10].
Multipotent stem cells of mother’s milk
It has been demonstrated that in vitro they can 
proceed in the differentiation process up to the 
formation of specific cells of the several tissues 
(hepatic, pancreatic, nervous and glial, adipose 
cells, chondrocytes, osteoblasts, cardiomyocytes) 
and can synthesize the specific proteins of the 
single cell line (insulin, albumin) [6-10]. A 
particularly interesting fact having to do with the 
therapeutic applications that may derive from this 
is the capacity that the hBSCs have in culture: that 
of spontaneously forming neurons, astrocytes and 
oligodendrocytes [6].
During the differentiation process it can be 
observed that genes typical of hESC are first 
upregulated and then downregulated with the 
appearance of upregulation of genes specific to 
the cell line at the same time. 
However, contrary to hESC, the pluripotent 
cells deriving from MM are unable to cause 
tumors if injected into experimental animals, but 
may integrate and regenerate damaged tissues 
when inoculated into severely immunodeficient 
mice [10]. We can thus conclude that MM 
expresses a population of hBSCs similar, but not 
identical, to hESCs.
Variability in the composition of human 
breastmilk-derived stem cells of mother’s milk
The individual and interindividual variability 
in the quali/quantitative composition of MM is 
well known. From a review of the literature it 
emerges that this variability is confirmed also for 
hBSCs [2, 10, 11]. In general what is observed is 
a progressive reduction of the number of cells in 
MM as lactation progresses. The expression of TFs 
and other genes involved in cell differentiation 
presents an interindividual and intraindividual 
variability, but it also changes in relation to the 
state of breast repletion. A major expression of 
genes OCT4, NANOG and SOX2 in women who 
breastfed and were pregnant at the same time has 
also been noted.
Origin of human breastmilk-derived stem cells
The cell heterogeneity of MM reflects that of 
the lactating mammary gland. The origin of hBSCs 
was debated for a long time. Once the hypothesis 
of their hematic origin was rejected, that of 
their fetal origin was advanced. The process of 
bidirectional migration of fetal and maternal cells 
through the placenta is in fact known. These cells 
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remain in various fetal tissues for a long period 
of time and may proliferate and differentiate into 
other kinds of cells [12]. It was thought that a 
subpopulation of cells from fetal tissues may 
reside in the breast after delivery and pass into the 
milk. However, it has recently been demonstrated 
that there is no fetal microchimerism in MM cells 
[8, 13].
In all likelihood, the hBSCs arrive from the 
mammary gland where they were present in the 
embryonic period in a state of quiescence by 
means of a mechanism that is not completely 
known (by migration or as the consequence of 
mechanical forces). The mammary origin of 
hBSCs has recently been confirmed by the finding 
of stem cells that express TFs typical of hESC 
within the lumen of the glandular ducts [10].
Already in 1959 the existence of mammary 
stem cells (MaSCs) was hypothesized on the basis 
of the mammary gland’s ability to expand during 
pregnancy and differentiate into a secretory organ 
during lactation [14].
The mammary gland is an organ that in a 
woman’s lifetime goes through different stages 
depending mostly on stimuli of a hormonal 
nature. In pregnancy it undergoes a remodeling 
process with a ten-fold increase in the lobules 
and alveoli [15]. MaSCs are present in reduced 
numbers in the quiescent mammary gland and 
are arranged in the basal layer of the ducts: they 
are multipotent and express surface antigens 
CD5/CD49f+/CD29+/CD24low/CK5+. During 
pregnancy they proliferate and determine the 
transformation of the mammary gland into a 
secretory organ. As stem cells, they are capable 
of self-renewal, but also of differentiating into 
the two kinds of mammary epithelial cells: the 
luminal cells CK18, the ductal cells CK19, and 
into the myoepithelial cells CK14/SMA.
Recently, cells that express the embryonic TFs 
OCT4, SOX2, NANOG, TRA-1-60/TRA-1-81 in 
the lactating mammary gland have been found. 
They are located in the epithelium and lumen of 
the ducts and alveoli. The latter discovery has led 
to the hypothesis of the existence of hESC-like 
cells in MM [10].
Although the hierarchy of MaSCs is known, 
all the markers and properties of these cells are 
not yet known since studies have mostly been 
performed on quiescent mammary glands or 
those affected by pathologies. Few are the studies 
performed on lactating mammary glands owing 
to a lack of autopsy or biopsy material. 
The role of the human breastmilk-derived stem 
cells
The stem cells of MM are capable of integration 
and differentiation into the several tissues. 
Similar to what takes place in the leukocytes, 
the hBSCs assumed in the milk can pass through 
the neonate’s intestinal barrier and, through the 
hematic circle, can reach the different organs. This 
is a phenomenon of microchimerism similar to 
what takes place through the placenta in the fetus. 
This was recently discovered by Hassiotou [1, 11]. 
In the mouse, the TdT+ cells contained in MM and 
administered to wild-type offspring were found 
first in the stomach (attached to the wall), then 
in the blood and thymus, liver, pancreas, brain 
and spleen. Some of these cells expressed OCT4, 
NANOG and CD49f. In the mouse tissues a double 
population of TdT+ was found: one expressed 
undifferentiated markers (OCT4, NANOG and 
CD49f), the other specific markers of the tissue, 
thus indicating a differentiation in the host. 
Even after weaning, it was possible to find in the 
different organs of the adult mice TdT+ cells from 
MM [1, 11].
Considerations and conclusions
The recent discovery of hBSCs in MM and 
especially their pluripotency, makes it imperative to 
continue studies on its qualitative cell composition 
and the effects and functions that these have in 
breastfed children.
The small number of studies and MM samples 
analyzed and the different sampling methods 
applied suggest standardization in the collection, 
analysis and culture of MM in future studies, 
in consideration of the well-known extreme 
variability of MM composition, also from the 
standpoint of cells.
The analysis of data thus far collected in the 
literature confirms the uniqueness of MM and its 
enormous potential: the noninvasiveness of sample 
collection, the high number and heterogeneity of 
the stem cell component it contains make it the 
principal means now available for the study of 
human stem cells.
We can thus conclude that on the basis 
of present-day knowledge of MM there is a 
heterogeneity/hierarchy of cells and stages of 
development that make it inimitable both as a 
nutrient and a biological liquid.
Some issues remain open [16, 17]: 
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r what epigenetic factors act on ESC TFs 
and on hBSCs of the subsequent stages of 
differentiation?
r what conditions of the mother/child dyad 
interfere in the qualitative and quantitative 
composition of hBSCs, analogous to what takes 
place in the leukocytes?
r is it possible to arrive at an understanding of 
what metabolic processes are at the base of 
and regulate the development/differentiation of 
hBSCs through metabolomic studies?
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